An interventional study of Theta Burst Transcranial Magnetic Bilateral Stimulation and Theta Burst Transcranial Magnetic Sham Stimulation in Resistant Depression, Treatment and Bipolar Depression, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain — 4 open to participants now, 5 under way, 2 of them phase 3. Depressive Disorder, Treatment-Resistant · Spain.
Among the 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain, this one is the 12th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2021, is one of 4 with no phase, and was the 11th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–74
Dr. Inge Winter · Sites in Spain, Austria, Germany and 3 more countries
Ages 18–65
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–78
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 196 across the 17 interventional studies, 830 across the 1 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 58 studies on the registry; 12 are open to participants now.
Instituto de Investigacion Sanitaria La Fe has 1 study filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
1 of the studies in Depressive Disorder, Treatment-Resistant with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07422519Hospital Universitari Vall d'Hebron Research InstituteVirtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder, Treatment-Resistant with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Theta Burst Transcranial Magnetic Stimulation (TBS) in dorsolateral prefrontal cortex (DLPFC) has shown efficacy and safety as an adjuvant strategy for resistant to treatment depression (RTD) in daily sessions during 4-6 weeks (20-30 sessions). Current investigation in TBS aims to design intensive treatment protocols so as to achieve earlier responses and higher rates of efficacy. However, the implementation of TBS in the Public National Health Service requires cost-effective protocols that ensure and facilitate patients adherence to treatment, and whose design is based on clinical and neuroimaging biomarkers of response so as to adequately select candidate patients. The aim of this study is to assess the efficacy and safety of novel bilateral and unilateral intensive and spaced protocols of TBS in outpatients with unipolar and bipolar RTD compared with sham stimulation. Specific objectives: I) Comparison of mood change, response and remission of depressive illness at the end of TBS protocol in the groups and maintenance of its effect at 3 months; II) Characterization of neuroimaging cerebral connectivity networks and cerebral metabolism patterns of patients with RTD related to the effects of bilateral or unilateral TBS; III) Identification of clinical and demographic predictors contributing to response to TBS; IV) Analysis of the interaction between clinical, demographic and neuroimaging predictors so as to determine a RTD profile of patient that can benefit from TBS.
Participants will receive 22 bilateral sessions of sham/active continuous (right DLPFC) and intermittent (left DLPFC) TBS during 6 weeks. Simultaneous cerebral PET-MRI will be performed before (week 0) and after the treatment with TBS (week 7)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
32 patients, bilateral active TBS stimulation, Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Continuous TBS in right DLPFC
Device: Theta Burst Transcranial Magnetic Bilateral Stimulation
32 patients, unilateral left DLPFC active TBS stimulation. Will receive an intensive-spaced protocol Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
Device: Theta Burst Transcranial Magnetic Unilateral Stimulation
32 patients, bilateral sham TBS stimulation. Will receive an intensive-spaced protocol of Sham Intermittent TBS in left DLPFC and Sham Continuous TBS in right DLPFC
Device: Theta Burst Transcranial Magnetic Sham Stimulation
TMS protocol of 22 sessions of bilateral active 1800 pulses.
TMS protocol of 22 sessions of sham bilateral 1800 pulses.
TMS protocol of 22 sessions of left active 1800 pulses and right sham 1800 pulses.
Hamilton Depression Rating Scale 17 items (HDRS-17) at the end of the treatment respect to basal.
Hetero-administered
Time frame: 6 weeks
Beck Depression Inventory (BDI-II) respect to basal.
Self-administered
Time frame: 2, 6 weeks
Montgomery Asberg Depression Rating Scale (MADRS) respect to basal.
Hetero-administered
Time frame: 2, 6 weeks
Young Mania Rating Scale (YMRS) at the end of the treatment respect to basal.
Hetero-administered
Time frame: 2, 6 weeks
Altman Self Rating Mania Scale (ASRM) at the end of the treatment respect to basal.
Self-administered
Time frame: 2, 6 weeks
Clinical Global Impression Scale (CGI) respect to basal.
Hetero-administered
Time frame: 2,6 weeks
Hamilton Anxiety Scale (HAM-A) respect to basal.
Hetero-administered
Time frame: 2,6 weeks
Oviedo Sleep Questionnaire (OSQ) respect to basal.
Hetero-administered
Time frame: 2, 6 weeks
Dimensional Apathy Scale (DAS) respect to basal
Self-administered
Time frame: 6 weeks
Screening for Cognitive Impairment por Psychiatry (SCIP) at the end of the treatment respect to basal.
Hetero-administered (versions A and B)
Time frame: 6 weeks
Short Form Health Survey (SF 36) at the end of the treatment respect to basal.
Self-administered
Time frame: 6 weeks
Functional Assessment Short Test (FAST) at the end of the treatment respect to basal.
Hetero-administered
Time frame: 6 weeks
Global assessment of Functioning (GAF) at the end of the treatment respect to basal.
Hetero-administered
Time frame: 6 weeks
Response to treatment
50% reduction in HDRS-17
Time frame: 2 and 6 weeks
Response to treatment
50% reduction in MADRS
Time frame: 2 and 6 weeks
Remission
HDRS-17\<8 points
Time frame: 2 and 6 weeks
Remission
MADRS\<11 POINTS
Time frame: 2 and 6 weeks
Plan to share: No
Started Sep 2021 (actual). Primary completion is estimated for Feb 2025, 41 months after the start.
Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 41 months is close to that.
Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Instituto de Investigacion Sanitaria La Fe